A Science|Business closed-door online workshop, organised in partnership with Sanofi, on the new EU BARDA-type agency
The COVID crisis has ignited the need for a strategy to protect Europe against supply chain interruptions, notably for medical equipment, but also pharmaceuticals. After coming under criticism for falling short in matching US support for COVID-19 vaccines and therapeutics development, the European Commission committed to unprecedented levels of public investment into COVID-19 vaccines development. It has agreed outline deals to purchase millions of doses from several drug companies. In parallel, President Ursula von der Leyen, in her recent State of the Union address, announced the establishment the new EU Health Emergency Preparedness and Response Authority (HERA), an equivalent to the US Biomedical Advanced Research and Development Authority, BARDA. A legislative proposal to set up the agency is tabled in the fourth quarter of 2021.
These announcements, symbols of a clear ambition to strengthen the EU’s capacity and preparedness to respond to cross-border health threats and emergencies, do raise several unresolved questions such as:
- How will HERA function, especially in terms of governance?
- Where will this new EU body fit between EU4Health and Horizon Europe programmes, both subject to severe budget cuts by the European Council?
- Does the policy response to the COVID crisis set new grounds for public-private collaboration in health?
- The European Commission is making the case for increased competences in health at the EU level. But are EU member states ready for this?
Science|Business is bringing together a select group of high-level academic, industry and policy experts, from the EU, the US and international organisations, to draw a set of recommendations related to the purpose, the role and the governance of this new authority. A public roadmap will be published in February 2021.
For more information on this by invitation only event, please contact Lysiane Pons ([email protected])